{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:48:46Z","timestamp":1794437326213,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinases 2\/4\/6 (CDK2\/4\/6) play critical roles in cell cycle progression, and their deregulations are hallmarks of hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the combination of computational and experimental approaches to discover a CDK2\/4\/6 triple-inhibitor from FDA approved small-molecule drugs for the treatment of HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified vanoxerine dihydrochloride as a new CDK2\/4\/6 inhibitor, and a strong cytotoxicdrugin human HCC QGY7703 and Huh7 cells (IC50: 3.79\u00a0\u03bcM for QGY7703and 4.04\u00a0\u03bcM for Huh7 cells). In QGY7703 and Huh7 cells, vanoxerine dihydrochloride treatment caused G1-arrest, induced apoptosis, and reduced the expressions of CDK2\/4\/6, cyclin D\/E, retinoblastoma protein (Rb), as well as the phosphorylation of CDK2\/4\/6 and Rb. Drug combination study indicated that vanoxerine dihydrochloride and 5-Fu produced synergistic cytotoxicity in vitro in Huh7 cells. Finally, in vivo study in BALB\/C nude mice subcutaneously xenografted with Huh7 cells, vanoxerine dihydrochloride (40\u00a0mg\/kg, i.p.) injection for 21\u00a0days produced significant anti-tumor activity (p\u2009&lt;\u20090.05), which was comparable to that achieved by 5-Fu (10\u00a0mg\/kg, i.p.), with the combination treatment resulted in synergistic effect. Immunohistochemistry staining of the tumor tissues also revealed significantly reduced expressions of Rb and CDK2\/4\/6in vanoxerinedihydrochloride treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study isthe first report identifying a new CDK2\/4\/6 triple inhibitor vanoxerine dihydrochloride, and demonstrated that this drug represents a novel therapeutic strategy for HCC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-021-00269-4","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T07:16:44Z","timestamp":1613114204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Discovery of vanoxerine dihydrochloride as a CDK2\/4\/6 triple-inhibitor for the treatment of human hepatocellular carcinoma"],"prefix":"10.1186","volume":"27","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Bin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Kun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Mei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Guo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong-Sak","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Hon","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ge","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Nan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Chia-mi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"2","key":"269_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery. 2015;14(2):130\u201346.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"269_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235\u201342.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"269_CR3","first-page":"1496","volume":"282","author":"HN Bramson","year":"1997","unstructured":"Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Therap. 1997;282(3):1496\u2013502.","journal-title":"J Pharmacol Exp Therap"},{"issue":"6","key":"269_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1751-0813.1996.tb07575.x","volume":"74","author":"MS Bull","year":"1996","unstructured":"Bull MS, Swindale S, Overend D, Hess EA. Suppression of Boophilus microplus populations with fluazuron\u2013an acarine growth regulator. Aust Vet J. 1996;74(6):468\u201370.","journal-title":"Aust Vet J"},{"issue":"7","key":"269_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4161\/cbt.19589","volume":"13","author":"M Canavese","year":"2012","unstructured":"Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther. 2012;13(7):451\u20137.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"269_CR6","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.ajpath.2012.01.016","volume":"180","author":"Y Che","year":"2012","unstructured":"Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol. 2012;180(5):1798\u2013807.","journal-title":"Am J Pathol"},{"issue":"1","key":"269_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/BF01962176","volume":"7","author":"NX Chin","year":"1988","unstructured":"Chin NX, Figueredo VM, Novelli A, Neu HC. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent. Eur J Clin Microbiol Infect Dis. 1988;7(1):58\u201363.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"17","key":"269_CR8","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/sj.onc.1208619","volume":"24","author":"D Cobrinik","year":"2005","unstructured":"Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24(17):2796\u2013809.","journal-title":"Oncogene"},{"issue":"4","key":"269_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2125.1992.tb05638.x","volume":"34","author":"P Danjou","year":"1992","unstructured":"Danjou P, Molinier P, Berlin I, Patat A, Rosenzweig P, Morselli PL. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol. 1992;34(4):328\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"19","key":"269_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2165\/00003495-200363190-00002","volume":"63","author":"LE Donnelly","year":"2003","unstructured":"Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 2003;63(19):1973\u201398.","journal-title":"Drugs"},{"issue":"3","key":"269_CR11","first-page":"383","volume":"42","author":"B Giros","year":"1992","unstructured":"Giros B, Godinot N, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol. 1992;42(3):383\u201390.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"269_CR12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","volume":"72","author":"I Gojo","year":"2013","unstructured":"Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol. 2013;72(4):897\u2013908.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"269_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000102061","volume":"79","author":"P Goldsmith","year":"2007","unstructured":"Goldsmith P, Golder Z, Hunt J, et al. GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility. Pharmacology. 2007;79(4):250\u20138.","journal-title":"Pharmacology"},{"issue":"3\u20134","key":"269_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0014-2999(84)90483-7","volume":"103","author":"RE Heikkila","year":"1984","unstructured":"Heikkila RE, Manzino L. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol. 1984;103(3\u20134):241\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"269_CR15","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","volume":"19","author":"M Hinz","year":"1999","unstructured":"Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition. Mol Cell Biol. 1999;19(4):2690\u20138.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"269_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.hrthm.2015.02.014","volume":"12","author":"C Howard","year":"2015","unstructured":"Howard C, Dittrich A, et al. COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. Heart Rhythm. 2015;12(6):1105\u201312.","journal-title":"Heart Rhythm"},{"issue":"1","key":"269_CR17","first-page":"178","volume":"258","author":"LL Howell","year":"1991","unstructured":"Howell LL, Byrd LD. Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. J Pharmacol Exp Therap. 1991;258(1):178\u201385.","journal-title":"J Pharmacol Exp Therap"},{"issue":"1","key":"269_CR18","first-page":"190","volume":"283","author":"LL Howell","year":"1997","unstructured":"Howell LL, Landrum AM. Effects of chronic caffeine administration on respiration and schedule-controlled behavior in rhesus monkeys. J Pharmacol Exp Therap. 1997;283(1):190\u20139.","journal-title":"J Pharmacol Exp Therap"},{"issue":"8","key":"269_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/1878-0261.12072","volume":"11","author":"FS Hsieh","year":"2017","unstructured":"Hsieh FS, Yao L, et al. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4\/6-independent manner. Mol Oncol. 2017;11(8):1035\u201349.","journal-title":"Mol Oncol"},{"issue":"1","key":"269_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1021\/acs.jcim.5b00299","volume":"56","author":"Z Huang","year":"2016","unstructured":"Huang Z, Wong CF. Inexpensive method for selecting receptor structures for virtual screening. J Chem Inf Model. 2016;56(1):21\u201334.","journal-title":"J Chem Inf Model"},{"issue":"4","key":"269_CR21","doi-asserted-by":"publisher","first-page":"e34460","DOI":"10.1371\/journal.pone.0034460","volume":"7","author":"T Huang","year":"2012","unstructured":"Huang T, Wang J, Cai Y-D, Yu H, Chou K-C. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS ONE. 2012;7(4):e34460.","journal-title":"PLoS ONE"},{"issue":"3","key":"269_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1254\/jjp.78.303","volume":"78","author":"A Ikeno","year":"1998","unstructured":"Ikeno A, Sumiya T, Minato H, Fujitani B, Masuda Y, Hosoki K, Kurono M, Yasuba M. Effects of monatepil maleate, a new Ca2+ channel antagonist with alpha1-adrenoceptor antagonistic activity, on cholesterol absorption and catabolism in high cholesterol diet-fed rabbits. Jpn J Pharmacol. 1998;78(3):303\u201312.","journal-title":"Jpn J Pharmacol"},{"issue":"1","key":"269_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin JJ, Shoichet BK. ZINC\u2013a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45(1):177\u201382.","journal-title":"J Chem Inf Model"},{"issue":"7","key":"269_CR24","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","volume":"52","author":"JJ Irwin","year":"2012","unstructured":"Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012;52(7):1757\u201368.","journal-title":"J Chem Inf Model"},{"issue":"11","key":"269_CR25","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1039\/c3mb70089e","volume":"9","author":"M Jiang","year":"2013","unstructured":"Jiang M, Chen Y, Zhang Y, Chen L, Zhang N, Huang T, Cai YD, Kong X. Identification of hepatocellular carcinoma related genes with k-th shortestpaths in a protein-protein interaction network. Mol Biosyst. 2013;9(11):2720\u20138.","journal-title":"Mol Biosyst"},{"issue":"2","key":"269_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","volume":"9","author":"A Jindal","year":"2019","unstructured":"Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221\u201332.","journal-title":"J Clin Exp Hepatol"},{"issue":"22","key":"269_CR27","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/jnci\/84.22.1736","volume":"84","author":"G Kaur","year":"1992","unstructured":"Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86\u20138275. J Natl Cancer Inst. 1992;84(22):1736\u201340.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"269_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0002-9440(10)65593-9","volume":"153","author":"H Kawana","year":"1998","unstructured":"Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol. 1998;153(2):505\u201313.","journal-title":"Am J Pathol"},{"issue":"2","key":"269_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1034\/j.1600-0676.2000.020002173.x","volume":"20","author":"H Kim","year":"2000","unstructured":"Kim H, Lee MJ, Kim MR, Chung IP, Kim YM, Lee JY, Jang JJ. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver. 2000;20(2):173\u20138.","journal-title":"Liver"},{"issue":"3","key":"269_CR30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1124\/jpet.104.076554","volume":"312","author":"EL Lane","year":"2005","unstructured":"Lane EL, Cheetham S, Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Therap. 2005;312(3):1124\u201331.","journal-title":"J Pharmacol Exp Therap"},{"key":"269_CR31","doi-asserted-by":"crossref","unstructured":"Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, Ribas A, Sondak VK: SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. J Clin Oncol. 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.8521"},{"issue":"3","key":"269_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1046\/j.0106-9543.2002.01629.x","volume":"22","author":"KK Li","year":"2002","unstructured":"Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, Poon RY. Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver. 2002;22(3):259\u201368.","journal-title":"Liver"},{"key":"269_CR33","doi-asserted-by":"crossref","unstructured":"Li H, Leung KS, Wong MH: idock: A multithreaded virtual screening tool for flexible ligand docking. In: 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB): 2012.","DOI":"10.1109\/CIBCB.2012.6217214"},{"issue":"1","key":"269_CR34","doi-asserted-by":"publisher","first-page":"e85678","DOI":"10.1371\/journal.pone.0085678","volume":"9","author":"H Li","year":"2014","unstructured":"Li H, Leung KS, Ballester PJ, Wong MH. istar: a web platform for large-scale protein-ligand docking. PLoS ONE. 2014;9(1):e85678.","journal-title":"PLoS ONE"},{"issue":"4","key":"269_CR35","first-page":"3296","volume":"19","author":"W Li","year":"2020","unstructured":"Li W, Chen QF, Huang T, Shen L, Huang ZL, Wu P. Profiles of m6ARNA methylation regulators for the prognosis of hepatocellular carcinoma. Oncol Lett. 2020;19(4):3296\u2013306.","journal-title":"Oncol Lett"},{"issue":"15","key":"269_CR36","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079\u201393.","journal-title":"Development"},{"issue":"7","key":"269_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","volume":"12","author":"JM Llovet","year":"2015","unstructured":"Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(7):408\u201324.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"269_CR38","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1128\/MCB.16.12.6917","volume":"16","author":"J Lukas","year":"1996","unstructured":"Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996;16(12):6917\u201325.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"269_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"269_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1540-8167.2009.01622.x","volume":"21","author":"N Matsumoto","year":"2010","unstructured":"Matsumoto N, Khrestian CM, Ryu K, Lacerda AE, Brown AM, Waldo AL. Vanoxerine, a new drug for terminating atrial fibrillation and flutter. J Cardiovasc Electrophysiol. 2010;21(3):311\u20139.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"269_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5493\/wjem.v6.i1.21","volume":"6","author":"R Mazzanti","year":"2016","unstructured":"Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: where are we? World J Exp Med. 2016;6(1):21\u201336.","journal-title":"World J Exp Med"},{"issue":"2","key":"269_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/10054","volume":"1","author":"P Meraldi","year":"1999","unstructured":"Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol. 1999;1(2):88\u201393.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"269_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","volume":"14","author":"MM Mita","year":"2014","unstructured":"Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer. 2014;14(3):169\u201376.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"269_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1254\/fpj.90.105","volume":"90","author":"T Nagase","year":"1987","unstructured":"Nagase T, Ishiko J, Takaori S. Effects of 1- [2- [bis(fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on turnover of dopamine and norepinephrine in the brain. Folia Pharmacologica Japonica. 1987;90(2):105\u201314.","journal-title":"Folia Pharmacologica Japonica"},{"issue":"2","key":"269_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1254\/fpj.90.105","volume":"90","author":"T Nagase","year":"1987","unstructured":"Nagase T, Ishiko J, Takaori S. Effects of 1- [2- [bis(fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on turnover of dopamine and norepinephrine in the brain. Nihon yakurigaku zasshi Folia pharmacologica Japonica. 1987a;90(2):105\u201314.","journal-title":"Nihon yakurigaku zasshi Folia pharmacologica Japonica"},{"issue":"2","key":"269_CR46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1254\/fpj.98.2_121","volume":"98","author":"T Nagase","year":"1991","unstructured":"Nagase T, Hotta K, Morita S, Sakai K, Yamane M, Omote M, Mizusawa H. Pharmacological effects of the novel dopamine uptake inhibitor 1- [2- [bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on the central nervous system. Nihon yakurigaku zasshi Folia pharmacologica Japonica. 1991;98(2):121\u201341.","journal-title":"Nihon yakurigaku zasshi Folia pharmacologica Japonica"},{"key":"269_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.biochi.2013.10.004","volume":"97","author":"J Nemet","year":"2014","unstructured":"Nemet J, Jelicic B, Rubelj I, Sopta M. The two faces of Cdk8, a positive\/negative regulator of transcription. Biochimie. 2014;97:22\u20137.","journal-title":"Biochimie"},{"issue":"2","key":"269_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93\u2013115.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"269_CR49","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9(8):2344\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"269_CR50","doi-asserted-by":"publisher","first-page":"13855","DOI":"10.1074\/jbc.273.22.13855","volume":"273","author":"J Peng","year":"1998","unstructured":"Peng J, Marshall NF, Price DH. Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J Biol Chem. 1998;273(22):13855\u201360.","journal-title":"J Biol Chem"},{"issue":"1","key":"269_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers7010179","volume":"7","author":"M Peyressatre","year":"2015","unstructured":"Peyressatre M, Prevel C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers. 2015;7(1):179\u2013237.","journal-title":"Cancers"},{"issue":"9","key":"269_CR52","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.hrthm.2016.04.012","volume":"13","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Pritchett ELC, Davison BA, et al. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Heart Rhythm. 2016;13(9):1777\u201383.","journal-title":"Heart Rhythm"},{"issue":"2","key":"269_CR53","first-page":"241","volume":"1","author":"A Preti","year":"2000","unstructured":"Preti A. Vanoxerine National Institute on Drug Abuse. Curr Opin Invest Drugs. 2000;1(2):241\u201351.","journal-title":"Curr Opin Invest Drugs"},{"issue":"3","key":"269_CR54","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/A:1006353008903","volume":"17","author":"AM Senderowicz","year":"1999","unstructured":"Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 1999;17(3):313\u201320.","journal-title":"Invest New Drugs"},{"issue":"10","key":"269_CR55","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/hepr.13353","volume":"49","author":"S Shen","year":"2019","unstructured":"Shen S, Dean DC, Yu Z, Duan Z. Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. Hepatol Res. 2019;49(10):1097\u2013108.","journal-title":"Hepatol Res"},{"issue":"7","key":"269_CR56","doi-asserted-by":"publisher","first-page":"e0132072","DOI":"10.1371\/journal.pone.0132072","volume":"10","author":"XN Shi","year":"2015","unstructured":"Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC. In silico identification and in vitro and in vivo validation of anti-psychotic drug fluspirilene as a potential CDK2 inhibitor and a candidate anti-cancer drug. PLoS ONE. 2015a;10(7):e0132072.","journal-title":"PLoS ONE"},{"issue":"5","key":"269_CR57","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.3892\/mmr.2015.4310","volume":"12","author":"XN Shi","year":"2015","unstructured":"Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lin MC. Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma. Mol Med Rep. 2015b;12(5):6501\u20138.","journal-title":"Mol Med Rep"},{"issue":"3","key":"269_CR58","first-page":"1592","volume":"40","author":"X Shi","year":"2018","unstructured":"Shi X, Li H, Shi A, Yao H, Ke K, Dong C, Zhu Y, Qin Y, Ding Y, He YH, et al. Discovery of rafoxanide as a dual CDK4\/6 inhibitor for the treatment of skin cancer. Oncol Rep. 2018;40(3):1592\u2013600.","journal-title":"Oncol Rep"},{"issue":"1\u20132","key":"269_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF01253052","volume":"61","author":"A Sietnieks","year":"1985","unstructured":"Sietnieks A. Involvement of 5-HT2 receptors in the LSD- and L-5-HTP-induced suppression of lordotic behavior in the female rat. J Neural Transm. 1985;61(1\u20132):65\u201380.","journal-title":"J Neural Transm"},{"issue":"1","key":"269_CR60","first-page":"142","volume":"251","author":"RD Spealman","year":"1989","unstructured":"Spealman RD, Madras BK, Bergman J. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Therap. 1989;251(1):142\u20139.","journal-title":"J Pharmacol Exp Therap."},{"issue":"3","key":"269_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","volume":"21","author":"LM Spring","year":"2019","unstructured":"Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4\/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 2019;21(3):25.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"269_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2013.11.020","volume":"83","author":"JJ Stephenson","year":"2014","unstructured":"Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, Statkevich P, Yao SL, Zhu Y, Zhou H, et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung cancer. 2014;83(2):219\u201323.","journal-title":"Lung cancer"},{"issue":"1","key":"269_CR63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbrc.2014.05.002","volume":"449","author":"T Sun","year":"2014","unstructured":"Sun T, Co NN, Wong N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochem Biophys Res Commun. 2014;449(1):163\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"269_CR64","first-page":"328","volume":"250","author":"JM Van Nueten","year":"1981","unstructured":"Van Nueten JM, Xhonneux R, Vanhoutte PM, Janssen PA. Vascular activity of ketanserin (R 41 468), a selective 5-HT2 receptor antagonist. Arch Int Pharmacodyn Ther. 1981;250(2):328\u20139.","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"20","key":"269_CR65","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","volume":"22","author":"AJ Walker","year":"2016","unstructured":"Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S, Sridhara R, Chen W, Palmby TR, Fourie Zirkelbach J, Fu W, et al. FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2016;22(20):4968\u201372.","journal-title":"Clin Cancer Res"},{"key":"269_CR66","unstructured":"Wang S, Zhu Y, Zheng X. Study and application of Chou-Talalay method for anti-tumor drug combination. Chin J Mod Appl Pharm. 2013."},{"issue":"7171","key":"269_CR67","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nature06358","volume":"450","author":"BA Weir","year":"2007","unstructured":"Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893\u20138.","journal-title":"Nature"},{"key":"269_CR68","doi-asserted-by":"crossref","unstructured":"Wikman H, Nymark P, Vayrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, Vainio-Siukola K, Husgafvel-Pursiainen K, Knuutila S, Wolf M et al: CDK4 is a probable target gene in a novel amplicon at 12q13.3-q141 in lung cancer. Genes Chromosomes Cancer 2005, 42(2):193\u2013199.","DOI":"10.1002\/gcc.20122"},{"issue":"6","key":"269_CR69","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/bjc.1995.238","volume":"71","author":"H Yamamoto","year":"1995","unstructured":"Yamamoto H, Monden T, Ikeda K, Izawa H, Fukuda K, Fukunaga M, Tomita N, Shimano T, Shiozaki H, Monden M. Coexpression of cdk2\/cdc2 and retinoblastoma gene products in colorectal cancer. Br J Cancer. 1995;71(6):1231\u20136.","journal-title":"Br J Cancer"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-021-00269-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10020-021-00269-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-021-00269-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T08:06:49Z","timestamp":1613117209000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-021-00269-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1186\/s10020-021-00269-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-29276\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-29276\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-29276\/v3","asserted-by":"object"}]},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal studies were approved by the Kunming Medical University\u2019s laboratory animal ethics committee. All authors have consented to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}